Although no established PRKCI inhibitors are available for clinical use (Jiao et al., 2023), PI3K enzyme inhibitors such as buparlisib and alpelisib have the potential to improve the therapeutic outcome in patients with HNSCC (Jung et al., 2018; Razak et al., 2023). This evidence concerns the gene PRKCI and head and neck squamous cell carcinoma.